Dermatologic Therapy最新文献

{"title":"Real-World Impact of Calcipotriol/Betamethasone Dipropionate Aerosol Foam on Quality of Life in Patients With Plaque Psoriasis: A Prospective Observational Study","authors":"Tiago Torres,&nbsp;Antonio Martorell,&nbsp;Paulo Leal Filipe,&nbsp;Caridad Soria,&nbsp;Fernando Mota,&nbsp;José Pardo,&nbsp;Miquel Ribera,&nbsp;Ricardo Ruiz-Villaverde","doi":"10.1155/dth/7529636","DOIUrl":"https://doi.org/10.1155/dth/7529636","url":null,"abstract":"<div>\u0000 <p><b>Background and Aim:</b> Quality of life (QoL) of psoriasis patients treated with calcipotriol/betamethasone dipropionate (Cal/BD) foam has not been thoroughly evaluated in real-world settings. This study evaluated the change in plaque psoriasis patients’ QoL after 4 weeks of first treatment with Cal/BD foam and after 6 months under daily practice conditions.</p>\u0000 <p><b>Methods:</b> A prospective, noninterventional study evaluated QoL, treatment adherence, satisfaction, and efficacy through the dermatology life quality index (DLQI), the Morisky-Green scale, the treatment satisfaction questionnaire for medication (TSQM-9), and the change in the body surface area (BSA) with plaque psoriasis, among others.</p>\u0000 <p><b>Results:</b> A total of 172 adult patients with plaque psoriasis were included. After 4 weeks of treatment, 53.5% of patients had a DLQI score ≤ 1. Mean absolute change in the DLQI score from baseline was −4.2 after 4 weeks of treatment and −4.0 after the 6-month follow-up (<i>p</i> &lt; 0.0001). Improvement in the BSA was statistically significant after the first treatment period and after the 6-month follow-up with a mean reduction of 2.4% and 2.6%, respectively (<i>p</i> &lt; 0.0001). Mean absolute change in global satisfaction between the end of the 4-week treatment period and the 6-month follow-up was −4.3 (<i>p</i> = 0.0049). In total, 41% of patients were compliant after the first treatment period, and 55.3% were moderately compliant. Higher patient treatment satisfaction was moderately correlated with lower DLQI scores after 4 weeks (<i>r</i> = −0.527; <i>p</i> &lt; 0.0001). Statistically significant differences between DLQI groups were found in the BSA: patients with DLQI ≤ 1 after 4 weeks of treatment had a lower BSA than patients with DLQI &gt; 1 (1.3 ± 1.8 vs. 2.8 ± 2.7, respectively; <i>p</i> &lt; 0.0001).</p>\u0000 <p><b>Conclusion:</b> After 4 weeks of treatment, daily use of Cal/BD foam in plaque psoriasis patients resulted in an improvement in QoL that was related to an improvement in both satisfaction and efficacy.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7529636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143698786","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug Survival in the Treatment of Mucosal Lichen Planus: A Retrospective Multicenter Study","authors":"Neda Cramer,&nbsp;Daniel Kromer,&nbsp;Julia M. Bootsveld,&nbsp;Sascha Gerdes,&nbsp;Petra Staubach-Renz,&nbsp;Katharina Assaf,&nbsp;Dagmar Wilsmann-Theis,&nbsp;Claudia Günther,&nbsp;Christian Kromer,&nbsp;Rotraut Mössner","doi":"10.1155/dth/8752339","DOIUrl":"https://doi.org/10.1155/dth/8752339","url":null,"abstract":"<div>\u0000 <p><b>Background and Objectives:</b> Mucosal lichen planus (LP) is a rare chronic inflammatory skin disease. Its treatment is difficult and comparative data on the sustainability of different drugs are lacking. We aimed to retrospectively assess patient and disease characteristics and analyze drug survival rates in the treatment of mucosal LP under real-world conditions.</p>\u0000 <p><b>Patients and Methods:</b> Our retrospective study included patients with mucosal LP treated systemically in the dermatology departments of five German University Medical Centers between 01/2005 and 03/2022. Patient and disease characteristics and treatment responses were evaluated. Drug survival from systemic therapies was assessed by Kaplan–Meier analysis and multivariate regression.</p>\u0000 <p><b>Results:</b> Overall, 281 patients with a total of 407 treatment courses were identified. The overall median drug survival was 5.0 months (conventional drugs: 5.0 months vs. novel drugs [biologicals and Janus kinase inhibitors]: 17.0 months, <i>p</i> = 0.029). Among conventional drugs, median drug survival was numerically the highest for methotrexate (13.0 months), followed by mycophenolate mofetil (12.0 months); hydroxychloroquine (9.0 months); acitretin and cyclosporine (6.0 months each); azathioprine, dapsone, and other retinoids (5.0 months each); and finally glucocorticoids (2.0 months). Among novel drugs, median drug survival was numerically the highest in TNF-α blockers and IL-17 antagonists (median: 21.0 and 17.0 months, respectively), while median drug survival for Janus kinase inhibitors has not yet been reached. Altogether, the outcomes were documented in 68.6% of cases, with excellent (33.5%), partial (34.5%) or nonresponse (32.0%) in one-third of cases each. The group of novel therapies comprising biologicals and Janus kinase inhibitors was significantly more effective than the group of conventional drugs (excellent response: 66.7%, 8/12 vs. 32.1%, 83/258; <i>P</i> = 0.013, <i>χ</i>²-test).</p>\u0000 <p><b>Conclusions:</b> In addition to glucocorticoids, cyclosporine, mycophenolate mofetil, and methotrexate (plus hydroxychloroquine), biologicals and Janus kinase inhibitors in particular seem to be therapeutic options for the treatment of mucosal LP, which is worth investigating further.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8752339","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A Novel Minimally Invasive Surgical Procedure for the Treatment of Steatocystoma Multiplex","authors":"Nan Zhang,&nbsp;Zepeng Li,&nbsp;Zhongke Xue,&nbsp;Weiling Wang,&nbsp;Yan Zheng,&nbsp;Wenwei Zhao","doi":"10.1155/dth/8623135","DOIUrl":"https://doi.org/10.1155/dth/8623135","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Steatocystoma multiplex (SM) is an asymptomatic benign skin lesion, characterized by multiple sebum-containing dermal cysts.</p>\u0000 <p><b>Objectives:</b> In this study, we report a novel surgical procedure of removal of the cysts followed by a 5-fluorouracil injection to fulfill the cosmetic needs of patients with SM.</p>\u0000 <p><b>Methods:</b> From January 2023 to January 2024, 35 patients with SM, 2 of whom showed septic steatocystoma, were surgically treated with the novel surgical method in the First Affiliated Hospital of Xi’an Jiaotong University. All procedures were performed in the outpatient operating room. Patients were in close follow-up for postoperative data, with the most recent follow-up until March 2024.</p>\u0000 <p><b>Results:</b> The surgical intervention is completed within a maximum duration of 40 min for each patient, and all 35 patients with SM exhibited complete postoperative wound healing with no relapse, no cicatrization, and limited hyperpigmentation in mere 4 patients (all within 3 months postoperatively), indicating a favorable overall cosmetic outcome at the latest follow-up in March 2024.</p>\u0000 <p><b>Conclusion:</b> Surgical removal of the cysts with subsequent 5-fluorouracil injection is a promising and novel operative procedure for SM which is minimally invasive, fulfills the cosmetic needs of the patients, and leads to no recurrence in any case.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8623135","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690171","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of Tofacitinib in Patients With Refractory Prurigo Nodularis: A 16-Week, Single-Center, Prospective, Observational Pilot Study","authors":"Ru Dai,&nbsp;Chao-Cheng Chi,&nbsp;Yuchen Lou,&nbsp;I-Jung Hsieh,&nbsp;Xiao-Yong Man","doi":"10.1155/dth/8988947","DOIUrl":"https://doi.org/10.1155/dth/8988947","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> The current management for prurigo nodularis (PN) is challenging. Tofacitinib may emerge as a promising treatment for PN.</p>\u0000 <p><b>Aim:</b> This study aimed to assess the efficacy and safety of tofacitinib in treating refractory PN.</p>\u0000 <p><b>Design and methods:</b> A 16-week prospective observational pilot study was conducted in patients with moderate-to-severe refractory PN. The enrolled patients received oral tofacitinib. The primary endpoints included improvement in pruritus and quality of life, as measured by investigator’s global assessment (IGA), prurigo activity score (PAS), visual analog scale (VAS), numeric rating scale (NRS), verbal rating scale (VRS), Dermatology Life Quality Index (DLQI), and Itchy Specific Quality of Life (Itchy QoL) at week 12. Secondary endpoints were the proportion of patients with a ≥ 4-point reduction in Worst Itch-Numeric Rating Scale (WI-NRS) from baseline at week 12 and week 16. Safety assessments were conducted through week 16. Besides, historical controls, mixed-effects model (MMRM), and post-hoc analyses were performed to evaluate the efficacy of tofacitinib.</p>\u0000 <p><b>Results:</b> Twenty-four PN patients included demonstrated clinical improvement in terms of skin lesions, pruritus, and quality of life. IGA, PAS items, VAS, NRS, VRS, DLQI, and Itchy QoL significantly improved from the baseline to 12 weeks of tofacitinib treatment (<i>p</i> &lt; 0.05 for all). However, the response to tofacitinib became less pronounced at week 16, with reduced improvement in skin lesions, itch, and quality of life compared to that at week 12. The percentage of patients experiencing a ≥ 4-point WI-NRS reduction decreased from 75% at week 12% to 66.67% at week 16. The results of historical controls, MMRM model, and post hoc analyses supported the clinical efficacy of tofacitinib in PN, with baseline NRS_24h,worst appearing to be a potentially clinical feature impacting treatment efficacy. No severe adverse events were reported up until the end of the study period.</p>\u0000 <p><b>Conclusions:</b> Tofacitinib demonstrates effectiveness in reducing itch and skin infiltration in patients with moderate-to-severe PN, whereas its long-term efficacy requires further observation.</p>\u0000 <p><b>Trial Registration:</b> ClinicalTrials.gov identifier: NCT06201715</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/8988947","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143690170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Alitretinoin for the Treatment of Lichen Amyloidosis: A Retrospective, Observational Study and an In Vitro Study","authors":"Eun Joo Baek,&nbsp;Sun Mee Shin,&nbsp;Seong Jun Kim,&nbsp;Kwang Ho Kim,&nbsp;Kwang Joong Kim,&nbsp;Eun Joo Park","doi":"10.1155/dth/7835429","DOIUrl":"https://doi.org/10.1155/dth/7835429","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Lichen amyloidosis (LA) is the most common form of localized cutaneous amyloidosis, often accompanied by severe pruritus. Treatment options are limited, and alitretinoin, a systemic retinoid, has shown promise in managing refractory cases.</p>\u0000 <p><b>Objective:</b> This study aimed to evaluate the efficacy of alitretinoin in treating LA and its effects on keratinocytes.</p>\u0000 <p><b>Methods:</b> We conducted a retrospective analysis of 13 patients diagnosed with LA treated with alitretinoin. In addition, an in vitro study assessed the impact of alitretinoin on keratinocyte inflammation markers.</p>\u0000 <p><b>Results:</b> Of the 13 patients, 4 (30.77%) achieved complete clearance of lesions, demonstrating excellent improvement. The remaining 9 (69.23%) showed substantial improvement, with almost clear or mild residual lesions. In vitro, alitretinoin significantly decreased levels of IL-33, periostin, CCL5, and PTGES.</p>\u0000 <p><b>Conclusion:</b> Alitretinoin demonstrated effectiveness in treating LA, with favorable outcomes in both clinical and in vitro settings. These findings support alitretinoin as a viable treatment option for LA.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7835429","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143689204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Circulating Cytokine Levels and the Risk of Hypertrophic Scar: A Two-Sample Mendelian Randomization Study","authors":"Xi Xu,&nbsp;Liwei Fang,&nbsp;Jinpeng Hu,&nbsp;Xinyi Li,&nbsp;Wei Zhang,&nbsp;Xiaojing Li","doi":"10.1155/dth/1582233","DOIUrl":"https://doi.org/10.1155/dth/1582233","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> Chronic inflammation has been implicated in hypertrophic scar (HS) formation based on experimental evidence and clinical observations. However, the existence of a causal relationship between circulating cytokines and the risk of HS remains uncertain. This study aimed to elucidate whether genetically predicted circulating cytokine levels are associated with HS risk using a two-sample Mendelian randomization (MR) analysis.</p>\u0000 <p><b>Methods:</b> We used genetic variants associated with circulating levels of cytokines in a genome-wide association study (GWAS) meta-analysis involving 8293 European populations as instrumental variables. HS data were obtained from an open GWAS dataset comprising 208,248 individuals of European descent, including 766 diagnosed HS cases and 207,482 controls. Analysis was performed using MR methods including inverse-variance weighted (IVW), MR-Egger, weighted median, simple median, and weighted mode. The MR-Egger intercept and Cochran’s Q test were applied to assess pleiotropy and heterogeneity, and MR Steiger test was employed to examine the causative direction.</p>\u0000 <p><b>Results:</b> Our findings revealed a suggestive causal relationship between elevated circulating levels of interleukin-2 (IL-2) and an increased risk of HS (OR: 1.48, 95% CI: 1.04–2.10, <i>p</i> = 0.028); platelet-derived growth factor-BB (PDGFbb) was also causally associated with the risk of HS (OR: 1.38, 95% CI: 1.07–1.77, <i>p</i> = 0.012).</p>\u0000 <p><b>Conclusion:</b> Our MR analysis provides suggestive evidence supporting a potential causal relationship between circulating IL-2, PDGFbb, and HS risk. Further research is warranted to explore how these cytokines influence the development of HS.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/1582233","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143645859","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Green-Synthesized Silver Nanoparticle Shampoo Created by Moringa and Bergamot Extraction Versus 2% Ketoconazole Shampoo for Scalp Seborrheic Dermatitis: A Prospective, Randomized, Double-Blinded, Controlled Trial","authors":"Piyakan Limtanyakul,&nbsp;Rithee Smithrithee,&nbsp;Panjaporn Wongwitthayakool,&nbsp;Malai Taweechotipatr,&nbsp;Pannawit Chottechathammanee,&nbsp;Somkiat Wattanasirichaigoon","doi":"10.1155/dth/7166552","DOIUrl":"https://doi.org/10.1155/dth/7166552","url":null,"abstract":"<div>\u0000 <p><b>Introduction:</b> Seborrheic dermatitis (SD) is one of the most common relapsing–remitting scalp diseases. The symptoms of SD are relieved by many treatments, including antifungal shampoos such as zinc pyrithione, selenium sulfide, and azole shampoos. This study aimed to investigate the effects of a shampoo containing green-synthesized silver nanoparticles (AgNPs) in relieving the symptoms of SD.</p>\u0000 <p><b>Methods:</b> Bergamot peel and moringa leaf extracts were green-synthesized to produce AgNP. Characteristic of AgNP particle was. The AgNPs were assessed to determine the minimum inhibitory concentration for <i>Malassezia furfur</i> and formulate the AgNP shampoo. Sixty patients with moderate to severe scalp SD were prospectively randomized into the 2% ketoconazole shampoo group (<i>n</i> = 30) and the AgNP shampoo group (<i>n</i> = 30). Scalp samples were collected for potassium hydroxide preparation and fungal culture for <i>Malassezia</i> species. The adherent scalp flaking score (ASFS), Dermatology Life Quality Index, and patient satisfaction were assessed.</p>\u0000 <p><b>Results:</b> After the first week, the ASFS was significantly lower in the AgNP shampoo group compared with the 2% ketoconazole shampoo group (<i>p</i> = 0.014,  <i>p</i> = 0.083). However, both shampoos significantly improved the ASFS at 2 and 4 weeks compared with the baseline. The improvements in the ASFS were not sustained at 1 month after discontinuing the use of either shampoo. The potassium hydroxide preparation and fungal culture could not identify the responsible fungus. The Dermatology Life Quality Index was significantly improved from baseline to Week 4 in the AgNP shampoo group (<i>p</i> = 0.026) but not the 2% ketoconazole shampoo group (<i>p</i> = 0.171). The overall patient-rated satisfaction levels were similar in the two groups. No adverse events were reported during the study, and there were no dropouts.</p>\u0000 <p><b>Conclusion:</b> Green-synthesized AgNP shampoo created using bergamot and moringa extract exhibited comparable efficacy to 2% ketoconazole shampoo in treating scalp SD.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/7166552","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143688982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy and Safety of GR1802 in Patients With Moderate-to-Severe Atopic Dermatitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial","authors":"Shangshang Wang,&nbsp;Litao Zhang,&nbsp;Yunsheng Liang,&nbsp;Shifa Zhang,&nbsp;Jingyan Wang,&nbsp;Xiaoyong Man,&nbsp;Chao Ji,&nbsp;Rixin Chen,&nbsp;Guang Xiang,&nbsp;Zudong Meng,&nbsp;Chunjun Yang,&nbsp;Hao Cheng,&nbsp;Qi Wang,&nbsp;Lin-feng Li,&nbsp;Siping Zhang,&nbsp;Yanfeng Ding,&nbsp;Quangang Zhu,&nbsp;Lanying Qin,&nbsp;Yumei Li,&nbsp;Qianjin Lu,&nbsp;Li Xia,&nbsp;Shuanglin Cao,&nbsp;Chunshui Yu,&nbsp;Xinsuo Duan,&nbsp;Liming Wu,&nbsp;Chunlei Zhang,&nbsp;Congjun Jiang,&nbsp;Wei Wang,&nbsp;Jinhua Xu","doi":"10.1155/dth/6903760","DOIUrl":"https://doi.org/10.1155/dth/6903760","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> GR1802 is a newly developed, fully humanized monoclonal antibody targeting the interleukin-4 receptor alpha (IL-4Rα) subunit, which is a component common to both the IL-4 and IL-13 receptor complexes.</p>\u0000 <p><b>Objectives:</b> Our objective was to assess the efficacy of GR1802 in adult patients presenting with moderate-to-severe atopic dermatitis.</p>\u0000 <p><b>Methods:</b> In this clinical trial, patients with moderate-to-severe atopic dermatitis were randomly assigned to receive either 300 mg GR1802, 150 mg GR1802, or a placebo every 2 weeks for 16 weeks. Primary endpoints were the Eczema Area and Severity Index (EASI-75) response rates at Week 16. Secondary efficacy outcomes included responders at various evaluation points from baseline to study end: IGA 0/1 with ≥ 2-point improvement; EASI-75, EASI-90, and EASI-50; and ≥ 3- or ≥ 4-point improvements in weekly average daily PP-NRS score. Safety was evaluated throughout the study.</p>\u0000 <p><b>Results:</b> From August 2022 to February 2023, 120 patients were randomized to receive either GR1802 150 mg (<i>n</i> = 40), GR1802 300 mg (<i>n</i> = 40), or placebo (<i>n</i> = 40), with 107 completing the study. GR1802 demonstrated a higher proportion of patients achieving EASI-75 at Week 16 compared with the placebo group, and the observed differences in EASI-75 response rates were 39.1% (GR1802 300 mg vs. placebo, 95% CI 20.0–58.2, <i>p</i> = 0.0002) and 19.4% (GR1802 150 mg vs. placebo, 95% CI −0.8–39.7, <i>p</i> = 0.0740). The GR1802 300 mg group also showed greater efficacy on secondary endpoints compared to the GR1802 150 mg group. Serious adverse events occurred in 10% of placebo patients, 2.5% of the GR1802 150 mg group, and none in the GR1802 300 mg group. Treatment-emergent AEs occurred in 75.0% of the GR1802 150 mg group, 82.5% of the GR1802 300 mg group, and 85.0% of the placebo group.</p>\u0000 <p><b>Conclusions:</b> GR1802 was well tolerated and effective in moderate-to-severe AD patients, showing a dose–response trend at 150–300 mg.</p>\u0000 <p><b>Trial Registration:</b> Chinese Registry of Clinical Trials: ChiCTR2100051917</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/6903760","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143595483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The First Systematic Review and Meta-Analysis of Pharmacological and Nonpharmacological Procedural Treatments of Dark Eye Circles (Periorbital Hyperpigmentations): One of the Most Common Cosmetic Concerns","authors":"Arash Pour Mohammad,&nbsp;Roya Zeinali,&nbsp;Paria Jafary,&nbsp;Mahsa Mortaja,&nbsp;Alireza Jafarzadeh,&nbsp;Azadeh Goodarzi","doi":"10.1155/dth/9155535","DOIUrl":"https://doi.org/10.1155/dth/9155535","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> A notable trend has been observed toward procedural interventions for periorbital hyperpigmentation (POH), with a variety of pharmacological and nonpharmacological treatment modalities being introduced. This systematic review aims to provide a comprehensive evaluation of these diverse procedural treatments for POH in the medical literature.</p>\u0000 <p><b>Method:</b> A systematic search was performed in major databases up to 2023, and studies were evaluated for clinical improvement, patient satisfaction, and adverse events. The retrieved studies were categorized as lasers and light therapies, chemical peels, PRP, carboxytherapy, fillers and injections, microneedling, and combination therapies.</p>\u0000 <p><b>Results:</b> A total of 33 studies involving 1320 patients were evaluated. The meta-analysis of improvement rates revealed that lasers (fractional CO₂ and Q-switched or long-pulsed Nd: YAG) and combination treatments (microneedling + chemical peels or fillers + lasers) demonstrated the highest efficacy, with 82% and 75% of patients experiencing excellent or good (&gt; 50%) improvement, respectively. Chemical peels, carboxytherapy, and PRP were less effective, benefiting 63%, 54%, and 44% of patients in the same category, respectively. Although fillers and autologous fat injections showed marked improvement in 94% and 74% of patients, the comparison of their results was limited due to their representation by a single study in each category. Considering the meta-analysis of satisfaction rates, lasers and combination treatments also led, with 82% and 75% of patients expressing over 50% satisfaction with treatment, respectively. Adverse events were generally mild and transient across treatments. Common side effects of lasers included transient burning and erythema. The fractional CO₂ laser was associated with discomfort, pain, and edema, with a shorter duration of swelling and erythema when combined with PRP. Q-switched and picosecond Nd:YAG lasers had higher postinflammatory hyperpigmentation rates compared to carboxytherapy and the picosecond 755-nm laser. The most common adverse effect of chemical peeling was erythema, with glycolic acid showing the maximum incidence.</p>\u0000 <p><b>Conclusion:</b> This systematic review reveals that lasers and combination therapies are the most effective and satisfactory treatments for POH, with generally mild and transient adverse events. However, further studies comprising larger sample sizes, multiple-arm designs, and longer follow-ups are needed to enable more robust comparisons.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9155535","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143594868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Efficacy and Safety of Combining Phototherapy and Topicals in the Treatment of Atopic Eczema: A Systematic Review of the Current Evidence","authors":"Eva Knöps,&nbsp;Marlide R. Jukema,&nbsp;Phyllis I. Spuls,&nbsp;Louise A. A. Gerbens","doi":"10.1155/dth/9993910","DOIUrl":"https://doi.org/10.1155/dth/9993910","url":null,"abstract":"<div>\u0000 <p><b>Background:</b> In patients with atopic eczema (AE), phototherapy is often combined with topical therapy in order to achieve better disease control. While commonly used guidelines do recommend concomitant use of ointments, creams and ultraviolet (UV) radiation, details on how to apply a topical regimen in combination with phototherapy in an effective, safe and tolerable manner are currently not provided. This systematic review assesses the available evidence on whether and how the several types of topical therapies can be effectively and safely used in combination with phototherapy in the treatment of AE.</p>\u0000 <p><b>Methods:</b> An update of a 2021 Cochrane review’s search was conducted. Randomised controlled trials (RCTs) were included that studied the treatment of AE with phototherapy in one or more study arms, to ensure no RCTs that allowed for the concomitant use of topicals would be missed. Two authors performed study selection and extraction of topical therapy data.</p>\u0000 <p><b>Results:</b> A total of 33 studies were included. Twenty-nine studies reported on combining topical therapy with phototherapy. Of these studies, all allowed for the concomitant use of emollients, 13 allowed topical corticosteroids and 1 allowed a topical calcineurin inhibitor. One study investigated the efficacy of combining phototherapy and a topical agent. None of the remaining studies commented on the efficacy of combination therapy. Nine studies included details on the frequency of the use of topicals. Three studies reported on timing of emollients with regard to phototherapy. Six studies reported a topical base type (cream, ointment, jelly). No studies reported on safety. Risk of bias was assessed as ‘high’or as ‘some concerns’.</p>\u0000 <p><b>Conclusions:</b> Very limited data from RCTs exist on the efficacy, safety and methods of combining topical therapy with phototherapy in the treatment of AE. This results in a lack of detailed guidance on how to perform combination therapy, which is striking as the combination of topicals and UV is widely applied in daily practice.</p>\u0000 </div>","PeriodicalId":11045,"journal":{"name":"Dermatologic Therapy","volume":"2025 1","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1155/dth/9993910","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143554631","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}